Patient-led NGLY1 gene therapy reaches 10 patients but stalls on FDA data and funding gaps

Wilsey assembled researchers, Nobel advisers, and $70 million over a decade to target NGLY1 deficiency, an ultra-rare disorder causing developmental failure. The open-label trial administered the vector to 10 children including Grace; post-dose hospitalization in one case raised safety signals but also demonstrated the operational feasibility of family-run manufacturing and regulatory navigation. Observational natural-history data collected by the group supplied the control arm absent from most ultra-rare programs.

Traditional pharma rarely advances candidates for disorders affecting fewer than 100 patients because projected returns fall below development costs. Grace Science's model bypasses this by crowdsourcing capital and expertise, yet it collides with FDA requirements for substantial evidence that remain calibrated to larger populations. Recent federal rare-disease funding announcements have not closed the post-IND financing gap for groups lacking venture or large-pharma partners.

The case therefore tests whether regulators will accept single-arm trials augmented by patient-reported outcomes or demand additional controlled data that the sponsor cannot finance. Resolution will shape precedent for dozens of similar advocacy-led programs now entering the clinic.